Press release
Chemotherapy Induced Neutropenia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Enzychem Lifesciences Corporation, Aileron Therapeutics, Evive Biotech, Myelo therapeutics, BeyondSpring P
To Know in detail about the Chemotherapy Induced Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Neutropenia Market Forecast
https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Chemotherapy Induced Neutropenia Market Report:
• The Chemotherapy Induced Neutropenia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, there were around 1,816,200 cancer patients receiving chemotherapy as of 2021
• In the 7MM, there were around 1,816,200 cancer patients receiving chemotherapy as of 2021.In 2021, the US accounted for the largest number of cancer patients receiving chemotherapy, with around 705,300 cases. Japan has about 322,300 cancer patients receiving chemotherapy in 2021, placing it second out of 7MM countries
• In 2021, there were approximately 167,000 cancer patients receiving chemotherapy in the UK. It is anticipated that the number of these instances will rise during the projection period
• that in Germany in 2021, there were around 63,000 cases at low risk for CIN and approximately 147,000 cases at intermediate-high risk
• With approximately 97,800 occurrences of CIN in 2021, Germany had the greatest number of cases within the EU4. However, with just about 46,800 cases, Spain had the fewest CIN cases in 2021
• Key Chemotherapy Induced Neutropenia Companies: Enzychem Lifesciences Corporation, Aileron Therapeutics, Evive Biotech, Myelo therapeutics, BeyondSpring Pharmaceuticals, BeyondSpring Pharmaceuticals, Dong-A ST Co., Ltd., Tianjin SinoBiotech Ltd., Biocad, Tianjin SinoBiotech Ltd., Teva Branded Pharma, Sandoz GmbH, Kyowa Kirin Co., Ltd., Prothya Biosolutions, and others
• Key Chemotherapy Induced Neutropenia Therapies: EC-18, ALRN-6924, F-627 (Ryzneuta), Myelo001, Plinabulin, Pegfilgrastim, PEG-G-CSF, rHSA-GCSF 2.4mg, empegfilrastim, HSA-GCSF, Chemotherapy Regimen, LA-EP2006, pegfilgrastim, Mannan Binding Lectin (MBL), and others
• The Chemotherapy Induced Neutropenia epidemiology based on gender analyzed that out of the total patients on chemotherapy, maximum patients are at intermediate-high risk for CIN
• The Chemotherapy Induced Neutropenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chemotherapy Induced Neutropenia pipeline products will significantly revolutionize the Chemotherapy Induced Neutropenia market dynamics.
Chemotherapy Induced Neutropenia Overview
For cancer patients receiving chemotherapy, the main dose-limiting hazard is chemotherapy-induced neutropenia (CIN). It is linked to higher morbidity and early mortality, higher medical expenses, and interruptions in potentially curative therapies. It can result in febrile neutropenia (FN).
Get a Free sample for the Chemotherapy Induced Neutropenia Market Report
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Chemotherapy Induced Neutropenia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chemotherapy Induced Neutropenia Epidemiology Segmentation:
The Chemotherapy Induced Neutropenia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Chemotherapy Induced Neutropenia
• Prevalent Cases of Chemotherapy Induced Neutropenia by severity
• Gender-specific Prevalence of Chemotherapy Induced Neutropenia
• Diagnosed Cases of Episodic and Chronic Chemotherapy Induced Neutropenia
Download the report to understand which factors are driving Chemotherapy Induced Neutropenia epidemiology trends @ Chemotherapy Induced Neutropenia Epidemiology Forecast
https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Chemotherapy Induced Neutropenia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy Induced Neutropenia market or expected to get launched during the study period. The analysis covers Chemotherapy Induced Neutropenia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chemotherapy Induced Neutropenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chemotherapy Induced Neutropenia Therapies and Key Companies
• EC-18: Enzychem Lifesciences Corporation
• ALRN-6924: Aileron Therapeutics
• F-627 (Ryzneuta): Evive Biotech
• Myelo001: Myelo therapeutics
• Plinabulin: BeyondSpring Pharmaceuticals
• Pegfilgrastim: BeyondSpring Pharmaceuticals
• PEG-G-CSF: Dong-A ST Co., Ltd.
• rHSA-GCSF 2.4mg: Tianjin SinoBiotech Ltd.
• empegfilrastim: Biocad
• HSA-GCSF: Tianjin SinoBiotech Ltd.
• Chemotherapy Regimen: Teva Branded Pharma
• LA-EP2006: Sandoz GmbH
• pegfilgrastim: Kyowa Kirin Co., Ltd.
• Mannan Binding Lectin (MBL): Prothya Biosolutions
Discover more about therapies set to grab major Chemotherapy Induced Neutropenia market share @ Chemotherapy Induced Neutropenia Treatment Market
https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Chemotherapy Induced Neutropenia Market Strengths
• The growth in the cancer patient population, along with a rise in the comorbidities and use of certain drugs (chemotherapies) over the globe, is contributing to the rise in the incidence of CIN
• An increase in clinical trials activity for emerging therapies will boost the market
• Rising awareness about the disease among clinicians and patients
Chemotherapy Induced Neutropenia Market Opportunities
• Limited development in the mechanism of action of approved therapies in the market offers a great opportunity for the investment and development of emerging novel therapies
• Medications with better safety for long term use and low treatment duration are the current unmet need of the CIN market
• Low-cost therapies and therapies with good patient compliance might be the game-changer for the CIN treatment market
Scope of the Chemotherapy Induced Neutropenia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chemotherapy Induced Neutropenia Companies: Enzychem Lifesciences Corporation, Aileron Therapeutics, Evive Biotech, Myelo therapeutics, BeyondSpring Pharmaceuticals, BeyondSpring Pharmaceuticals, Dong-A ST Co., Ltd., Tianjin SinoBiotech Ltd., Biocad, Tianjin SinoBiotech Ltd., Teva Branded Pharma, Sandoz GmbH, Kyowa Kirin Co., Ltd., Prothya Biosolutions, and others
• Key Chemotherapy Induced Neutropenia Therapies: EC-18, ALRN-6924, F-627 (Ryzneuta), Myelo001, Plinabulin, Pegfilgrastim, PEG-G-CSF, rHSA-GCSF 2.4mg, empegfilrastim, HSA-GCSF, Chemotherapy Regimen, LA-EP2006, pegfilgrastim, Mannan Binding Lectin (MBL), and others
• Chemotherapy Induced Neutropenia Therapeutic Assessment: Chemotherapy Induced Neutropenia current marketed and Chemotherapy Induced Neutropenia emerging therapies
• Chemotherapy Induced Neutropenia Market Dynamics: Chemotherapy Induced Neutropenia market drivers and Chemotherapy Induced Neutropenia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chemotherapy Induced Neutropenia Unmet Needs, KOL's views, Analyst's views, Chemotherapy Induced Neutropenia Market Access and Reimbursement
To know more about Chemotherapy Induced Neutropenia companies working in the treatment market, visit @ Chemotherapy Induced Neutropenia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/chemotherapy-induced-neutropenia-cin-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Chemotherapy Induced Neutropenia Market Report Introduction
2. Executive Summary for Chemotherapy Induced Neutropenia
3. SWOT analysis of Chemotherapy Induced Neutropenia
4. Chemotherapy Induced Neutropenia Patient Share (%) Overview at a Glance
5. Chemotherapy Induced Neutropenia Market Overview at a Glance
6. Chemotherapy Induced Neutropenia Disease Background and Overview
7. Chemotherapy Induced Neutropenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Chemotherapy Induced Neutropenia
9. Chemotherapy Induced Neutropenia Current Treatment and Medical Practices
10. Chemotherapy Induced Neutropenia Unmet Needs
11. Chemotherapy Induced Neutropenia Emerging Therapies
12. Chemotherapy Induced Neutropenia Market Outlook
13. Country-Wise Chemotherapy Induced Neutropenia Market Analysis (2019-2032)
14. Chemotherapy Induced Neutropenia Market Access and Reimbursement of Therapies
15. Chemotherapy Induced Neutropenia Market Drivers
16. Chemotherapy Induced Neutropenia Market Barriers
17. Chemotherapy Induced Neutropenia Appendix
18. Chemotherapy Induced Neutropenia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Chemotherapy Induced Neutropenia Pipeline
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Chemotherapy Induced Neutropenia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chemotherapy Induced Neutropenia market. A detailed picture of the Chemotherapy Induced Neutropenia pipeline landscape is provided, which includes the disease overview and Chemotherapy Induced Neutropenia treatment guidelines.
Chemotherapy Induced Neutropenia Epidemiology
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chemotherapy Induced Neutropenia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Chemotherapy Induced Neutropenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.
Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chemotherapy Induced Neutropenia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Enzychem Lifesciences Corporation, Aileron Therapeutics, Evive Biotech, Myelo therapeutics, BeyondSpring P here
News-ID: 3475421 • Views: …
More Releases from DelveInsight Business Research
Vascular Dementia Market Report 2032: Epidemiology Data, Pipeline Therapies, Lat …
DelveInsight's "Vascular Dementia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Vascular Dementia, historical and forecasted epidemiology as well as the Vascular Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Vascular Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vascular Dementia Market Forecast
https://www.delveinsight.com/sample-request/vascular-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Limb Girdle Muscular Dystrophy Pipeline Assessment, 2024: FDA, EMA, and PMDA App …
Limb Girdle Muscular Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 25+ Limb Girdle Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Limb Girdle Muscular Dystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Limb Girdle Muscular Dystrophy Market.
The Limb Girdle Muscular Dystrophy…
RIPK1 Inhibitor Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approv …
RIPK1 Inhibitor pipeline constitutes 10+ key companies continuously working towards developing 12+ RIPK1 Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"RIPK1 Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the RIPK1 Inhibitor Market.
The RIPK1 Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the…
Atypical Teratoid Rhabdoid Tumors Pipeline Report, 2024 Updates : In-depth Analy …
Atypical Teratoid Rhabdoid Tumors pipeline constitutes 5+ key companies continuously working towards developing 5+ Atypical Teratoid Rhabdoid Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Atypical Teratoid Rhabdoid Tumors Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atypical Teratoid Rhabdoid Tumors Market.
The Atypical Teratoid Rhabdoid Tumors…
More Releases for Chemotherapy
Chemotherapy Devices Market 2022 Will Boom With Advanced Chemotherapy Technologi …
New Research Study ""Chemotherapy Devices Market 2022 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities), Size, Share and Outlook"" has been added to Coherent Market insight
The most recent Global Chemotherapy Devices Market report includes a high-level overview of the industry as well as in-depth analysis of key areas. The overview presented highlights the definition of products and services, as well as their associated applications, at the…
Cancer, chemotherapy and its treatment
Chemotherapy is one of the most commonly used cancer therapies. It employs the use of certain medications to destroy cancer cells or prevent them from spreading to other parts of the body. Chemotherapy may be prescribed alone or in combination with surgery or radiation therapy. Along with chemotherapy, you may also take newer types of cancer-fighting medications.
Chemotherapy can be taken as pills or as injections. You may visit a clinic…
Chemotherapy Devices Market Generated Opportunities, Future Scope 2021-2028 | Ad …
The Global Chemotherapy Devices Market, accounted for US$ 10.9 billion in 2017, and is expected to witness a 7.7% CAGR over the forecast period (2018 - 2026).
Technological advancements within cancer treatments including chemotherapy along with rising cancer care investments are decreasing the number of deaths caused by cancer worldwide. As per the 2016 study by Cancer Journal for Clinicians, the amount of cancer survivors grows continuously in the U.S.,…
Chemotherapy induced Nausea and Vomiting (CINV) TreatmentS Market Driven by Risi …
According to WHO cancer is one of the most leading causes for death with around 8 million deaths and 14 million new patients in 2012. Chemotherapy, which is received by approximately four million cancer patients each year, is among the most commonly used treatment to fight cancer. However, this mode of treatment has many side effects, an estimate of around 70% - 80% of the patients receiving chemotherapy treatment experience…
Nano Chemotherapy Market Nano Chemotherapy Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Nano Chemotherapeutics Mediations andndash; Solicitation to Nanomedicine
1.1 Overview
1.2 Nano Chemotherapeutics with Pharmaceutical Potential
Significance of Nano Chemotherapeutics to overcome the Chemotherapy Limitations
2.1 Limitations of Conventional Chemotherapy
2.2 Nanotechnology in Cancer Targeting
2.2.1 Active Targeting
2.2.2 Passive Targeting
2.2.3 pH Dependent Drug Delivery Through Nanoparticles
Role…
Nano Chemotherapy Is Emerging As An Important Anti-Cancer Modality By Supplement …
“Global Nano Chemotherapy Market and Clinical Trials Outlook 2022” report highlights the current development in the in the field of nano chemotherapy. Report gives comprehensive insight on various clinical and non-clinical parameters associated with the expansion of global nano chemotherapeutics market. The clinical and pricing insight on chemotherapeutics nanoformulations of approved drugs helps to understand the current market scenario of the nano chemotherapeutics.
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Download Report:…
